Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.63 |
| ▸ | SRC | P12931 | 17/20 | 0.62 |
| ▸ | SYK | P43405 | 15/20 | 0.62 |
| ▸ | GSK3A | P49840 | 14/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6546404 | 0.95 | MAPK14 (0.63) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6545894 | 0.93 | MAPK14 (0.59) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6545990 | 0.90 | MAPK14 (0.58) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6546000 | 0.90 | GSK3A (0.74) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6546366 | 0.90 | GSK3A (0.57) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6545989 | 0.89 | GSK3A (0.56) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6545930 | 0.89 | GSK3A (0.56) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6547546 | 0.89 | MAPK14 (0.62) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6545956 | 0.88 | GSK3A (0.62) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6547129 | 0.88 | MAPK14 (0.59) | MAPK14SRCSYKGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6765009-B2 | N-(5-TERT-BUTYL-3-(3-(4-((2-DIMETHYLAMINOMETHYL-PYRIDIN-4-YL) -PIPERAZIN-1-YL-METHYL) NAPHTHALEN-1-YL)UREIDO)-2-METHOXYPHENYL) METHANESULFONAMIDE FOR EXAMPLE; CYTOKINE INHIBITORS FOR TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-07-20 | — | — | US | disclosed |
| EP-1381592-A1 | 1,4-DISUBSTITUTED BENZO-FUSED COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030083333-A1 | 1,4-Disubstituted benzo-fused compounds | BOEHRINGER INTELHEIM PHARMACEUTICALS, INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2002083628-A1 | 1,4-DISUBSTITUTED BENZO-FUSED COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083333-A1 | 1,4-Disubstituted benzo-fused compounds | RELA, NFKBIA, NQO1 | MAPK14 3841/4885SRC 2052/4885SYK 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.